
WE CLAIM:


1. A process for the preparation of the compound of Formula I




(Formula I)

comprising the steps of:

reacting $Zn(CN)_2$ with the compound of Formula II, thereby forming the compound of Formula III




(Formula II)



(Formula III); and

forming the compound of Formula I by reacting the compound of Formula III with the compound of Formula IV



(Formula IV).

2. The process of claim 1, wherein the reaction of the compound of Formula II with $Zn(CN)_2$ occurs as follows:

1. reacting the compound of Formula II with $Zn(CN)_2$, $Zn(OAc)_2/Zn$, DMAC, and $Pd(dppf)_2Cl_2 \cdot CH_2Cl_2$;

2. reacting with water/acetone/MTBE/charcoal/$MgSO_4$/FLORISIL™/CELITE™; and

3. heptane.

3. The process of claim 2, wherein the compound of Formula III is crystalized in the heptane.

4. The process of claim 1, wherein the reaction of the compound of Formula III with the compound of Formula IV occurs as follows:

1. reacting the compound of Formula III with K_2CO_3, DMAC, HCl and the compound of Formula IV;

2. reacting with H_2O;

3. adding charcoal, $MgSO_4$ and CELITE™; and

4. adding EtOH.

5. The process of claim 4, wherein the compound of Formula I is crystalized in EtOH.

6. A pharmaceutical dosage form comprising a substantially pure form of (S)-(7-cyano-4-pyridin-2-ylmethyl-1,2,3,4-tetrahydro-cyclopenta[b]indol-2-yl)-carbamic acid isopropyl ester or a pharmaceutically acceptable salt thereof.

7. The dosage form according to claim 6 selected from a capsule.

8. A technical grade form of (S)-(7-cyano-4-pyridin-2-ylmethyl-1,2,3,4-tetrahydro-cyclopenta[b]indol-2-yl)-carbamic acid isopropyl ester or a pharmaceutically acceptable salt thereof.